Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4254704 | 0.88 | TSHR (0.44) | TSHRKDM4EALDH1A1HTTLMNA | |
| SCHEMBL4254582 | 0.88 | NPBWR1 (0.50) | KDM4EALDH1A1HTTLMNANPSR1 | |
| SCHEMBL4254361 | 0.84 | ALDH1A1 (0.52) | TSHRKDM4EALDH1A1HTTLMNA | |
| SCHEMBL27772585 | 0.80 | TSHR (0.48) | TSHRKDM4EALDH1A1HTTLMNA | |
| SCHEMBL4257847 | 0.80 | ALDH1A1 (0.44) | KDM4EALDH1A1HTTLMNANPSR1 | |
| SCHEMBL4252907 | 0.79 | CASP3 (0.43) | TSHRKDM4EPFKFB3MEN1KMT2A | |
| SCHEMBL4258174 | 0.79 | NPBWR1 (0.49) | KDM4EALDH1A1HTTLMNANPSR1 | |
| SCHEMBL3175610 | 0.77 | NOTUM (0.46) | KDM4EALDH1A1HTTLMNAHPGD | |
| SCHEMBL19000720 | 0.75 | TSHR (0.61) | TSHRKDM4EALDH1A1HTTLMNA | |
| SCHEMBL4259019 | 0.75 | CASP3 (0.36) | TSHRKDM4EALDH1A1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481537-B2 | Caspase inhibitors based of pyridazinone scaffold | LG LIFE SCIENCES LTD. (KR) | 2013-07-09 | — | — | US | disclosed |
| CN-101506174-B | Caspase inhibitors based on pyridazinone scaffold | LG LIFE SCIENCES LTD | 2012-05-02 | — | — | CN | disclosed |
| US-20090291959-A1 | CASPASE INHIBITORS BASED OF PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2009-11-26 | — | — | US | disclosed |
| CN-101506174-A | Caspase inhibitors based on pyridazinone scaffold | LG LIFE SCIENCES LTD (KR) | 2009-08-12 | — | — | CN | disclosed |
| EP-2046757-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG Life Sciences Ltd. (KR) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008016239-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291959-A1 | CASPASE INHIBITORS BASED OF PYRIDAZINONE SCAFFOLD | CASP1, CASP2, CASP5 | TSHR 4747/4885KDM4E 1607/4885ALDH1A1 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.